Nav: Home

Critical Path for Parkinson's Consortium achieves EMA support

October 10, 2016

London and Tucson, Ariz., October 10, 2016 -- The Critical Path Institute (C-Path), in partnership with Parkinson's UK, announced today that the European Medicines Agency (EMA) has issued a letter of support for Parkinson's disease (PD). EMA is supporting the use of an imaging biomarker as a tool to help researchers select people in the earliest stages of PD to participate in clinical trials of new treatments for the condition.

The EMA issued a letter of support on October 7, 2016, supporting the use of neuroimaging biomarker dopamine transporter imaging as an exploratory biomarker for early PD. The public letter was issued to the Critical Path for Parkinson's Consortium (CPP), in response to the consortium's submission of data supporting the use of the biomarker.

Dopamine transporter activity, as assessed by single-photon emission computed tomography (SPECT) imaging, measures the expression of dopamine nerve terminal function in the living brain. Low levels of dopamine transporter binding serve as a marker of the loss of dopamine nerve terminals, a hallmark of PD. Use of this biomarker in patients at the time of early clinical presentation will help to identify patients who are likely to show clinical progression of motor symptoms.

The letter of support is a step along the way to CPP's ultimate goal of achieving biomarker qualification with EMA and FDA. Why is EMA qualification significant? According to Dr. Arthur Roach, Director of Research at Parkinson's UK, qualification would relieve trial sponsors of the burden of having to convince the regulators that the biomarkers are reliable and reproducible every time they run a trial. "Qualification could save both the regulators and sponsors a tremendous amount of time and money." CPP's executive director, Diane Stephenson, states: "Parkinson's disease treatments are urgently needed, and shaving off time and cost serves to incentivize companies to invest in more trials.... More shots on goal mean more chances of getting approved drugs past the finish line."

Professor Donald Grosset, University of Glasgow, a key global leader in Parkinson's disease research that is contributing data to CPP, commented that embedding biomarkers in clinical trials, with support from regulatory agencies, could ultimately facilitate their use as both prognostic and therapeutic indicators. "This will all happen more quickly due to the significant progress we are making in sharing data across several major studies," Grosset wrote. "This action from the EMA is certainly good news for the field."

In 2015, the US Food and Drug Administration (FDA) issued a letter of support for this same biomarker and its application in drug development. These letters convey that the FDA and EMA recognize the potential value of a biomarker and encourage its further evaluation. A total of seven FDA and three EMA letters of support have been issued to C-Path.

Global regulatory agencies see value in compiling data from several sponsors in a noncompetitive setting, rather than receiving data from one sponsor at a time in support of biomarker qualification. Integration of data across different clinical trials and longitudinal studies is a core competency of C-Path and a key goal of the multinational CPP.
About C-Path

C-Path (Critical Path Institute) is an independent, nonprofit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona, and the US Food and Drug Administration (FDA). C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established 12 global, public-private partnerships that currently include over 1,450 scientists from government and regulatory agencies, academia, patient advocacy organizations, and dozens of major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona. For more information, visit

About Parkinson's UK

Every hour, someone in the UK is told they have Parkinson's. It affects 127,000 people in the UK--which is around one in 500 of the population. Parkinson's is a degenerative neurological condition, for which there currently is no cure. The main symptoms of the condition are tremor, slowness of movement and rigidity.

Parkinson's UK is the UK's leading charity supporting those with the condition. Its mission is to find a cure and improve life for everyone affected by Parkinson's through cutting edge research, information, support and campaigning. For advice, information and support, visit or call our free, confidential helpline on 0808 800 0303.

The Critical Path Institute (C-Path)

Related Clinical Trials Articles:

Giving children a voice in clinical trials
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.
Better health for women involved in clinical trials
Women who participate in obstetric and gynecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London.
Final artificial pancreas clinical trials now open
Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.
Why the bar needs to be raised for human clinical trials
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
New drug formulary will help expedite use of agents in clinical trials
The National Cancer Institute (NCI) today launched a new drug formulary (the 'NCI Formulary') that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
More Clinical Trials News and Clinical Trials Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...